- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Zydus Lifesciences Limited — Updates, 27-02-2026: Press Release
27-02-2026 | 02:50 pm
27-02-2026 | 02:50 pm
Zydus's biosimilar FYB206 (for Keytruda®) successfully met pivotal clinical study objectives, showing bioequivalence. This clears the path for US/Canada market entry, positioning Zydus as a potential first-wave player in the lucrative immuno-oncology biosimilar market (Keytruda® sales US$ 31.6 billion).
No comments yet. Be the first to comment!